BELLUS Health Inc trades with the ticker BLU on the TSX and is in the Biotechnology industry.
Overview
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.
Looking to invest in BELLUS Health Inc? Our analysis brings in the key facts, competitor research and valuation metrics for you to make an informed decision.
Table of Contents
show
BLU.TO Stock Price and Key Stats
ETF Key Stats
Exchange: TSX
Market Cap : $2470.298MM
PE Ratio:
Price: 0.07 (Updated: 3/12/2024 0:47:16)
BELLUS Health Inc (BLU) vs Competitors in Biotechnology
Lets see how BLU.TO stacks up against others in the Biotechnology asset management industry. We have identified its main peers as:Aeterna Zentaris Inc, Aptose Biosciences Inc, Fennec Pharmaceuticals Inc, IMV Inc, Intellipharmaceutics International Inc
.Biotechnology Industry Comparisons
| Company | Market Cap ($MM) | P/E Ratio | EV/EBITDA | Dividend Yield |
|---|---|---|---|---|
| Aeterna Zentaris Inc (AEZS) | $12.674 | N/A | 1.709 | N/A% |
| Aptose Biosciences Inc (APS) | $33.927 | N/A | -0.231 | N/A% |
| BELLUS Health Inc (BLU) | $2,470.298 | N/A | -16.428 | 0.0% |
| Fennec Pharmaceuticals Inc (FRX) | $352.565 | N/A | -21.793 | N/A% |
| IMV Inc (IMV) | $13.117 | N/A | -0.843 | 0.0% |
EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization – this ratio compares the value of a company, including debt, to the company’s cash earnings less non-cash expenses
Industry: companies that have a lot in common
Market Cap: Market Capitalization – the total value of all a corporation’s stock
N/A: Not Applicable or Not Available
P/E: Price-to-Earnings – this ratio relates a corporation’s share price to its earnings per share
Price: Stock Price – current value to buyers and sellers
Dividend Yield: Dividend or Distribution Yield
Comparisons within Biotechnology
- BELLUS Health Inc (BLU) vs Aeterna Zentaris Inc (AEZS)
- BLU has higher EPS (-0.96 vs -6.47). BLU provides dividends, while AEZS does not. AEZS and BLU both have P/E’s under 0.
- BELLUS Health Inc (BLU) vs Aptose Biosciences Inc (APS)
- BLU has higher EPS (-0.96 vs -10.45). BLU provides dividends, while APS does not. APS and BLU both have P/E’s under 0.
- BELLUS Health Inc (BLU) vs Fennec Pharmaceuticals Inc (FRX)
- BLU has higher EPS (-0.96 vs -1.01). BLU provides dividends, while FRX does not. FRX and BLU both have P/E’s under 0.
- BELLUS Health Inc (BLU) vs IMV Inc (IMV)
- BLU has higher EPS (-0.96 vs -6.11). IMV has higher dividend yield (0.0% vs 0.0%). IMV and BLU both have P/E’s under 0.
- BELLUS Health Inc (BLU) vs Intellipharmaceutics International Inc (IPCI)
- IPCI has higher EPS (-0.12 vs -0.96). BLU provides dividends, while IPCI does not. IPCI and BLU both have P/E’s under 0.
Our Recommendation: Hold
Features a lower EV/EBITDA ratio (-16.43) than the industry average (-8.21), indicating attractive valuation.
How to Buy BLU stock on the TSX
You can buy on pretty much any online brokerage in Canada, since it trades on the TSX. If you are looking for some easy options take a look at these two:| Image | Product Title | Features | Price |
|---|---|---|---|
Editor's Choice  |
| Get $25 Signup Bonus | |
Reliable Pick  |
| Get $50 Free Stock Trades |
